SCHEMBL378614

SCHEMBL378614

Cc1noc(-c2ccc(C(=O)N3CCC(C(=O)NC(c4ccc(F)cc4)C(F)(F)F)(c4ccc(F)cc4)CC3)cc2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSL P07711 1/20 0.42
CTSB P07858 1/20 0.42
CTSS P25774 1/20 0.42
CTSK P43235 1/20 0.42
TACR3 P29371 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
CYP1A2 P05177 1/20 0.40
BDKRB1 P46663 2/20 0.38
IDO1 P14902 1/20 0.38
STAT3 P40763 3/20 0.37
IKBKE Q14164 1/20 0.36
TBK1 Q9UHD2 1/20 0.36
GPR119 Q8TDV5 1/20 0.36
HDAC4 P56524 3/20 0.36
HDAC6 Q9UBN7 2/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
FASN P49327 2/20 0.36
KCNK3 O14649 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7910518 1.00 CTSL (0.42) CTSLCTSBCTSSCTSKTACR3
SCHEMBL13092467 1.00 CTSL (0.42) CTSLCTSBCTSSCTSKTACR3
SCHEMBL13092370 0.96 STAT3 (0.42) CTSLCTSBCTSSCTSKTACR3
SCHEMBL7908720 0.96 CTSL (0.42) CTSLCTSBCTSSCTSKTACR3
SCHEMBL379355 0.90 TACR3 (0.41) CTSLCTSBCTSSCTSKTACR3
SCHEMBL13092367 0.89 TACR3 (0.40) CTSLCTSBCTSSCTSKTACR3
SCHEMBL13092384 0.88 HDAC4 (0.42) TACR3STAT3HDAC4HDAC6HDAC2
SCHEMBL378669 0.86 TACR1 (0.41) TACR3CYP2C9CYP2C19CYP1A2BDKRB1
SCHEMBL13092251 0.86 BDKRB1 (0.40) TACR3CYP2C9CYP2C19CYP1A2BDKRB1
SCHEMBL7900653 0.86 PTPN1 (0.42) CTSLCTSBKCNK3PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
EP-2408745-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2012-01-25 EP disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
WO-2010106081-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 CTSL 1515/4885CTSB 1520/4885CTSS 1555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.